The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Individual patient data (IPD) pooled analysis on the optimal therapeutic management of patients with microsatellite instability-high (MSI) resectable gastroesophageal adenocarcinoma (GEA).
 
Alessandra Raimondi
Consulting or Advisory Role - MSD
Speakers' Bureau - Elma Academy; SERVIER
Travel, Accommodations, Expenses - Amgen; Merck Serono
 
Gabriele Tine'
No Relationships to Disclose
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); Gilead Sciences (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Helyon; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Gianmarco Ricagno
No Relationships to Disclose
 
Giovanni Cardellino
No Relationships to Disclose
 
Floriana Nappo
No Relationships to Disclose
 
Ferdinando De Vita
No Relationships to Disclose
 
Matthew Nankivell
No Relationships to Disclose
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); Roche (Inst)
 
Jeeyun Lee
Consulting or Advisory Role - AstraZeneca; Guardant Health AMEA; Mirati Therapeutics; Oncologie; Trutino Biosciences
Research Funding - AstraZeneca; Merck Sharp & Dohme
 
Won Ki Kang
No Relationships to Disclose
 
Jae-Ho Cheong
No Relationships to Disclose
 
Yoon Young Choi
No Relationships to Disclose
 
Alessio Polymeropoulos
No Relationships to Disclose
 
Chiara Pircher
No Relationships to Disclose
 
Rosalba Miceli
Honoraria - Boehringer Ingelheim
 
Guillaume Piessen
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Elivie; MSD Oncology; Nestle health science; Stryker
Travel, Accommodations, Expenses - medtronic; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Medtronic
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Seagen; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation